<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329666</url>
  </required_header>
  <id_info>
    <org_study_id>AAAF1846</org_study_id>
    <secondary_id>R01DK084986</secondary_id>
    <nct_id>NCT01329666</nct_id>
  </id_info>
  <brief_title>Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D</brief_title>
  <official_title>Early Effect of Vitamin D in Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary hyperparathyroidism (PHPT) is a common disease that occurs in 1 in 10,000 people&#xD;
      every year. In the presence of this condition, the parathyroid glands produce excessive&#xD;
      amounts of parathyroid hormone (PTH), which regulates calcium levels. The high levels of&#xD;
      parathyroid hormone remove too much calcium from bones, and then deposit the excess calcium&#xD;
      in the blood, which is then filtered into the urine by the kidneys. Bone health is threatened&#xD;
      by excess calcium loss which weakens bone structure. Other affected organs include the&#xD;
      skeleton (calcium loss leads to a &quot;weakening&quot; of the skeleton), and the kidneys (high blood&#xD;
      calcium can lead to kidney stones).&#xD;
&#xD;
      It is now evident that the majority of patients with even mild Primary Hyperparathyroidism&#xD;
      are vitamin D deficient. In 2009, new international guidelines for the management of&#xD;
      asymptomatic PHPT direct physicians to measure 25-hydroxyvitamin D (D3 or 25-OHD) in all&#xD;
      patients, and to replete the reserve of vitamin D when the level is low (&lt; 20 ng/ml).&#xD;
      However, no recommendations for vitamin D repletion are given, because of limited data&#xD;
      regarding the effects of vitamin D repletion, appropriate dosing and safety. Therefore, there&#xD;
      is an urgent need for data upon which to base such recommendations, as well as are data on&#xD;
      the effects of such treatment upon bones.&#xD;
&#xD;
      Subjects with low vitamin D3 levels will be selected for this trial. They will be given&#xD;
      enough vitamin D3 to raise their low blood levels from a low to a normal range. The&#xD;
      assessments in this study, including the quadruple label bone biopsy, will allow us to&#xD;
      document the short term effects of administering vitamin D3 on changes in bone.&#xD;
&#xD;
      All participants enrolled in this trial will be vitamin D3 deficient. Participants will take&#xD;
      an antibiotic (tetracycline) 4 times a day to mark the starting point from which bone changes&#xD;
      will be assessed. After 3 days of tetracycline, a 12 week course of vitamin D3 or placebo&#xD;
      will be initiated. Six of 7 participants will receive the study drug (active vitamin D3),&#xD;
      while 1 in 7 will receive a placebo (sugar pill). Ten weeks later, another 3-day course of&#xD;
      tetracycline will be given. At the end of 12 weeks, a bone biopsy will be done. A small piece&#xD;
      of bone (about the size of a pencil eraser) will be removed from the hip (iliac crest). The&#xD;
      bone will be analyzed to determine the effect of vitamin D3 on primary hyperparathyroidism.&#xD;
&#xD;
      There will be 4 study visits: Screening, Baseline, Week 8, and Week 12 when the bone biopsy&#xD;
      will be performed.&#xD;
&#xD;
      Study Procedures:&#xD;
&#xD;
      Medical and Social History&#xD;
&#xD;
      Blood tests (drawn at the study center and local Quest Lab)&#xD;
&#xD;
      24-Hour urine collection for calcium and creatinine excretion&#xD;
&#xD;
      Abdominal X-ray (to assess for kidney stones)&#xD;
&#xD;
      Transiliac crest Bone Biopsy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Poor enrollment&#xD;
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bone Formation Rate (BFR)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>A between group (vitamin D3 vs. placebo) comparison of BFR will be performed at three surfaces, cancellous, intra- and endo-cortical.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <condition>Hypercalcemia</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>50,000 IU Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (inactive Vitamin D3)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.</description>
    <arm_group_label>Placebo (inactive Vitamin D3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Baseline:&#xD;
50,000 IU/week for 8 weeks&#xD;
Week 8:&#xD;
Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.&#xD;
Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks.</description>
    <arm_group_label>50,000 IU Vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females and males &gt;= 45 years of age&#xD;
&#xD;
          2. PHPT, defined as elevated PTH with elevated serum calcium&#xD;
&#xD;
          3. Screening 25-OHD &lt;= 20 ng/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-menopausal&#xD;
&#xD;
          2. Serum calcium is &gt;11.5mg/dl.&#xD;
&#xD;
          3. Urinary calcium is &gt;350 mg/dl.&#xD;
&#xD;
          4. Active nephrolithiasis&#xD;
&#xD;
          5. Nephocalcinosis&#xD;
&#xD;
          6. Known sensitivity to tetracycline (Sumycin)&#xD;
&#xD;
          7. Familial history of hyperparathyroid syndromes&#xD;
&#xD;
          8. Bisphosphonate use within past 2 years.&#xD;
&#xD;
          9. Current use of Prolia.&#xD;
&#xD;
         10. Current use of Cinacalcet.&#xD;
&#xD;
         11. Currently using Cimetidine.&#xD;
&#xD;
         12. Currently use Colestipol.&#xD;
&#xD;
         13. Currently using Orlistat.&#xD;
&#xD;
         14. Current or past malignancy, except cured basal or squamous cell skin carcinoma or&#xD;
             other cancers that have not recurred for at least five years.&#xD;
&#xD;
         15. Current tuberculosis, or history of Sarcoidosis, HIV/AIDS, chronic kidney disease&#xD;
             (serum creatinine &gt;= 1.5), liver disease, Crohn's Disease, Celiac Disease, or gastric&#xD;
             bypass&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shonni J. Silverberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Shonni J. Silverberg</investigator_full_name>
    <investigator_title>Professor of Medicine, Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Primary Hyperparathyroidism</keyword>
  <keyword>Endocrinology</keyword>
  <keyword>Hypercalcemia</keyword>
  <keyword>Vitamin D deficiency</keyword>
  <keyword>Parathyroid Hormone</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Bone Density</keyword>
  <keyword>Vitamin D repletion</keyword>
  <keyword>Vitamin D Supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

